Clinical Guidance on COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

This guidance is intended for health-care providers and is based on known evidence as of November 8, 2022.

Background and Context

- Some patients with significant autoimmune/inflammatory diseases of the neurologic system (including the brain, spinal cord, motor nerves, neuromuscular junction and muscles – referred to broadly as neuromuscular) require treatment with immunotherapies. 1
- These diseases (including multiple sclerosis, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and inflammatory myopathy) result from immune tolerance dysfunction such that the patient’s immune system attacks their own tissues.
- Patients with neuromuscular conditions who require treatment with immunosuppressive medications are at increased risk of hospitalization and mortality from COVID-19.2

This guidance is based on a review of the vaccines approved by Health Canada for the prevention of COVID-19 disease caused by the SARS-CoV-2 virus:

- **mRNA vaccines:** tozinameran (COMIRNATY, Pfizer-BioNTech),3 tozinameran and riltozinameran (COMIRNATY Bivalent original & BA.1, Pfizer-BioNTech),4 tozinameran and famtozinameran (COMIRNATY Bivalent original & BA.4/BA.4, Pfizer-BioNTech),5 elasomeran (SPIKEVAX, Moderna),6 elasomeran and imelasomeran (SPIKEVAX Bivalent original & BA.1, Moderna)7
- **Viral vector vaccine:** ChADOx1-S (VAXZEVRIA, AstraZeneca),8 Ad26.COV2.S (JCVODEN, Janssen)9
- **Recombinant protein vaccine:** COVID-19 Vaccine (recombinant protein, adjuvanted) (NUVAXOVID, Novavax)10
- **Plant based virus-like particle (VLP) vaccine:** COVID-19 Vaccine ([VLP], recombinant, adjuvanted) (COVIFENZ, Medicago)11

Currently, anyone in British Columbia (B.C.) who is aged 6 months and older is eligible for COVID-19 immunization. The mRNA vaccine SPIKEVAX (Moderna) and COMIRNATY (Pfizer-BioNTech) have been approved for children 6 months to 11 years of age, with young children getting a smaller dose of the same vaccine used for youth and adults.12 National Advisory Committee on Immunization (NACI) has released their statement for these age groups.13,14,15
People who receive the mRNA vaccine (COMIRNATY [Pfizer-BioNTech] or SPIKEVAX [Moderna]) for their first dose, will be offered either mRNA vaccine for subsequent doses, with the exception of preferential recommendations based on age and immunosuppression. B.C. has taken the proactive step to expand booster doses for all individuals 5 years and older, not just those at high risk. However, it is particularly recommended for individuals 5-17 years of age who are at higher risk of severe illness due to COVID-19 infection. All booster doses will be mRNA vaccines. For those who are not able, or willing, to receive mRNA vaccines, Novavax is available as an alternative for individuals 18 years of age and older.

**Third doses as part of primary vaccine series:**

Recent studies demonstrate that some people who are immunocompromised develop an improved antibody response after a third dose of vaccine. Therefore, people who are moderately to severely immunocompromised in B.C. are eligible to receive a third dose of an mRNA COVID-19 vaccine as part of their primary vaccine series. NACI recommends the SPIKEVAX (Moderna) for children 6 months to 4 years of age. A minimum interval of 28 days between dose 2 and dose 3 is recommended for those eligible for a third dose. As per the B.C. Immunization Manual, SPIKEVAX (Moderna) is preferred for children 6 months to 4 years of age and COMIRNATY (Pfizer-BioNTech) is recommended for those 5-11 years of age. For individuals 12 years of age and older, SPIKEVAX (Moderna) is preferred for the third dose, but if it is unavailable (or if the individual prefers), COMIRNATY (Pfizer-BioNTech) may be provided.

Specifics on current eligibility for a third dose may be reviewed here: [https://www2.gov.bc.ca/gov/content/covid-19/vaccine/register#immunocompromised](https://www2.gov.bc.ca/gov/content/covid-19/vaccine/register#immunocompromised)

**Booster doses:**

As part of the Fall 2022 booster dose program, B.C. is making plans to offer everyone 5 years and older a booster dose. NACI has been clear this approach will provide the best protection in the Fall and Winter when we’re all spending more time inside and respiratory illness is passed around our communities.

SPIKEVAX BIVALENT BA.1 (Moderna) (50 mcg) is the preferred product in B.C. for moderately to severely immunosuppressed individuals 12 years and older. SPIKEVAX original (Moderna) (100 mcg) primary series has been associated with a higher seroconversion rate among immunocompromised adult patients compared to COMIRNATY original (Pfizer-BioNTech) (30 mcg). In a general population of adults, booster vaccination with SPIKEVAX original (Moderna) (50 mcg) was also found to be more effective than COMIRNATY original (Pfizer-BioNTech) (30 mcg) during a period of Delta followed by Omicron variant dominance. However, these studies were conducted prior to the emergence of the Omicron BA.4/BA.5 Variant of Concern (VOC), and their applicability to all Omicron sublineages is uncertain. Health Canada has recently authorized an adapted version of the SPIKEVAX (Moderna) COVID-19 vaccine that targets the Omicron BA.4/BA.5 subvariants.

**Patients who have tested positive for COVID-19:**

Booster doses may be deferred in those who have tested positive for COVID-19 until 3-6 months from symptom onset or, for asymptomatic cases, from the time of the positive test. This suggested interval is based on immunological principles and expert opinion. When considering whether or not to administer vaccine doses following the suggested 3-6-month interval, biological and social risk factors for exposure (e.g., local epidemiology, circulation of VOCs, living
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

**Updated: November 8, 2022**

Settings) and severe disease should also be taken into account. As these intervals are to be used as a guide, clinical discretion is advised.

COVID-19 vaccination may be offered to individuals at any time following recovery from SARS-CoV-2 infection.

**Intervals between doses:**

Individuals requesting a shorter interval between doses should be informed that this actually offers less optimal protection, but their request for an earlier dose should be granted, without need for Medical Health Officer approval, provided the minimum interval between doses has been observed.

The minimum interval between completion of the primary series, or a previous booster dose, and the Fall booster dose is 3 months. This revised minimum interval additionally applies to pregnant people and aligns with NACI’s updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding. The exception to this is JCVODEN (Janssen) for which the minimum interval is 8 weeks between the single dose of JCVODEN (Janssen) and the booster dose.

**Other vaccines:**

**VAXZEVRIA (AstraZeneca)**

The VAXZEVRIA (AstraZeneca) vaccine program has been stopped in B.C. for first doses, unless there is a contraindication to the mRNA vaccines, or as advised by the Medical Health Officer or an allergist, due to infrequent (1:50,000) but serious Vaccine-Induced Thrombotic Thrombocytopenia (VITT) blood clotting events after the first dose. The Government of Canada is not securing additional VAXZEVRIA doses.

**JCVODEN (Janssen)**

The JCVODEN one-dose viral vector vaccine is now available in limited supply in B.C. However, mRNA vaccines are preferred over viral vector vaccines due to better effectiveness and immunogenicity of mRNA vaccines and the possible adverse effects specifically associated with viral vector vaccines (e.g., Thrombosis and Thrombocytopenia Syndrome [TTS]). A viral vector COVID-19 vaccine should only be considered when all other authorized COVID-19 vaccines are contraindicated or have been refused, due to the reduced effectiveness and the possible adverse effects associated with viral vector vaccines (e.g., TTS). The Food and Drug Administration (FDA) have issued a for the Janssen COVID-19 vaccine about the increased risk of developing Guillain-Barré syndrome (GBS) in the 42 days after vaccination.

**NUVAXOVID (Novavax)**

NUVAXOVID is a different class of vaccination, a protein subunit vaccine that will give British Columbians another option to protect themselves against COVID-19 infection. NUVAXOVID may be offered to individuals for whom COVID-19 mRNA vaccines are contraindicated or have been refused. This vaccine is available to people aged 18 years and older. It is a two-dose vaccine and a limited number of doses will be available in B.C.
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

COVIFENZ (Medicago)\textsuperscript{11}

COVIFENZ\textsuperscript{11} is a different class of vaccination, a plant-based virus-like particle vaccine that will give British Columbians another option to protect themselves against COVID-19 infection. COVIFENZ is approved for people who are 18 to 64 years of age. It is a two-dose vaccine and a limited number of doses will be available in B.C.\textsuperscript{11} This product is not yet available in Canada.

People were generally excluded from COVID-19 vaccine trials if they were on immunosuppressant treatment. Therefore, there are still uncertainties as to whether COVID-19 vaccine is efficacious and safe in patients with autoimmune neuromuscular disorders on therapy, as well as to the timing of immunization in relation to their treatments.\textsuperscript{1,33}

Is COVID-19 immunization recommended for patients with neuromuscular disorders receiving immunosuppressive/immunomodulating therapy?

COVID-19 immunization should be encouraged for patients with neuromuscular disorders receiving immunosuppressive/immunomodulating therapy and is not contraindicated, including those who have had COVID-19 infection. This recommendation is based on the following review:

- The National Advisory Committee on Immunization recommends that immunosuppressed individuals may be offered the vaccine if the benefits of vaccine outweigh the potential risks.\textsuperscript{16}
- Based on the GBS/CIDP Foundation Global Medical Advisory Board’s \textit{statement} on November 11, 2021: “We recommend vaccination for all GBS, CIDP, and MMN patients as soon as possible as per their provincial authorities... If a patient has developed their disease within 6 weeks after receiving a COVID-19 vaccination, the patient should make an informed consent after discussing the risks versus benefits with their healthcare professional about receiving a second dose of vaccine that is of a different type, preferentially mRNA, as per the NACI guidance.”\textsuperscript{34}
- Based on the \textit{statement} from the National Multiple Sclerosis (MS) Advisory Board/ The Canadian Network of Multiple Sclerosis Clinics Statement on February 10, 2021: “Most people with relapsing and progressive forms of MS should be vaccinated. The risks of COVID-19 disease outweigh any potential risks from the vaccine...The vaccines are not likely to trigger an MS relapse or to worsen your chronic MS symptoms. The risk of getting COVID-19 far outweighs any risk of having an MS relapse from the vaccine.”\textsuperscript{35}

While data specific to the safety and efficacy of the Pfizer and Moderna COVID-19 vaccines in people who take immunosuppressant or immunomodulating therapies is currently limited, there are data to suggest that the currently available COVID-19 vaccines have efficacy.\textsuperscript{36} The authors of this guidance agree that the benefits of vaccine-induced immunity against COVID-19 for this population outweigh any theoretical risks of immunization.

The risks of COVID-19 infection to neuromuscular patients treated with immunotherapy include the following factors:
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

- During the COVID-19 pandemic, patients with neuromuscular disorders may be at greater risk of worse outcomes than otherwise healthy people because of an immunocompromised state related to immunotherapy. Immunosuppressive therapies can limit immune competence.32,35 This can affect the risk of infections37,38; some therapies are associated with an increased risk from particular types of pathogens.
  - Patients with autoimmune neuromuscular disorders (such as myasthenia gravis) who are infected with SARS-CoV-2 are frequently admitted to hospitals, have disease exacerbations and a higher mortality than the general population with COVID-19.39
  - Patients must continue with immunotherapy to avoid increasing symptoms including weakness of respiratory and bulbar muscles; the risk of relapse may result in permanent disability.
- Infections are a well-recognised trigger of symptom exacerbation in autoimmune conditions such as myasthenia gravis and multiple sclerosis.40
- Individual considerations regarding the appropriateness of the vaccine in patients with neuromuscular disease include, but are not limited to:
  - Level of activity of virus in the patient’s local community
  - Individual risk of severe disease or death in patient contracting SARS-CoV-2 due to their neuromuscular condition and independent of their neuromuscular diagnosis (e.g., age and other comorbidities)
  - Whether family, care providers, and close contacts of the patient can receive immunization if they have no contraindication.

Is COVID-19 immunization efficacious and safe for patients with neuromuscular disorders receiving immunosuppressive/immunomodulating therapy?

- GBS cases following COVID-19 vaccination have been identified in Canada and internationally, but rarely.41 There does not appear to be an increase from baseline incidence with mRNA vaccines.42-44
- As per NACI, safety data in immunocompromised individuals, including those receiving immunosuppressive therapy, were available from observational studies in people who were taking immunosuppressive therapies.16 The frequency and severity of adverse events following vaccination with an mRNA COVID-19 vaccine were comparable to that of non-immunocompromised individuals in these studies and what was reported in clinical trials. Safety data in these populations following vaccination with a viral vector vaccine is not available.
- There is one study that suggests that a third dose of COVID-19 vaccine in immunocompromised patients can increase antibody levels.45 Small studies on third doses of the mRNA COVID-19 vaccines have shown that immunogenicity (immunity measured in the blood) may increase with a third dose. The safety of a third dose is unknown at this time, but in these small studies reactions were found to be similar to that of prior doses.
- Informed consent should include discussion about the possibility that individuals who are immunosuppressed may have a diminished immune response to any of the authorized COVID-19 vaccines, as well as a discussion about the emerging evidence on the safety of mRNA COVID-19 vaccines in these populations. The recommendations in this clinical guidance are based on these small observational studies, extrapolation of data from other viral infections, immunology of immunizations and from expert opinion.
- There is limited information on the effectiveness of vaccines in individuals who are on immunosuppressive medications.17 However, even reduced efficacy may confer benefits against COVID-19 infections.1
- As immune response to COVID-19 immunization is unknown for those taking immunosuppressant or immunomodulating therapy, patients with neuroimmunological disease who receive the COVID-19 vaccine...
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

should continue to closely follow public health recommendations including social distancing, regular hand washing and/or disinfection.

- An increased risk of developing autoimmune or inflammatory disorders was not observed in clinical trial participants who received an mRNA COVID-19 immunization compared to placebo. Rate of recurrent GBS is infrequent after mRNA COVID-19 vaccine.

Are there any specific contraindications or exceptions for patients with neuromuscular disorders receiving immunosuppressive/immunomodulating therapy?

### Allergy to vaccine components

Individuals who have had a severe allergic reaction to an ingredient of one type of COVID-19 vaccine are still able to receive future doses of the other type of vaccine. BCCDC has a list of the individual components and their purpose in the vaccines. For a complete list of components in the vaccine, consult the vaccine monographs found at: www.bccdc.ca/health-info/diseases-conditions/covid-19/covid-19-vaccine/vaccines-for-covid-19.

For individuals with a history of anaphylactic reaction to a previous dose of an mRNA COVID-19 vaccine, re-vaccination (i.e., administration of a subsequent dose in the series when indicated) may be offered with the same vaccine or the same mRNA platform if a risk assessment deems that the benefits outweigh the potential risks for the individual and if informed consent is provided. Prior to revaccination, consultation with an allergist or another appropriate physician (e.g., Medical Health Officer) is advised. If re-vaccination is going ahead, vaccine administration should be done in a controlled setting with expertise and equipment to manage anaphylaxis, with an extended period of observation of at least 30 minutes after re-vaccination.

Health Canada continues to monitor any adverse events following immunization through their post-authorization surveillance process.

### Guillain Barre Syndrome (GBS)

Individuals with past history of Guillain Barre Syndrome (GBS) unrelated to COVID-19 vaccination should receive an mRNA COVID-19 vaccine. When mRNA COVID-19 vaccines are contraindicated or inaccessible, individuals may receive a viral vector COVID-19 vaccine after weighing the risks and benefits in consultation with their health care provider.

Individuals who developed GBS after a previous dose of a COVID-19 vaccine may receive another dose of an mRNA COVID-19 vaccine, after consultation with their health care provider (i.e., if the benefits outweigh the risk and informed consent is provided).

- No instances of GBS were seen during clinical trials of the Pfizer and Moderna mRNA vaccines, and neither the U.S. Centers for Disease Control and Prevention (CDC) nor the Food and Drug Administration (FDA) recommends against the vaccine due to GBS.
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

• The incidence of GBS in the United Kingdom decreased by 50% during the first wave of COVID-19, likely due to COVID-19 control measures put in place which reduced the incidence of viral infection generally, compared to the same period during the four years prior. 47

• An analysis of the genetic and protein structure of SARS-CoV-2 showed that it contains no additional immunogenic material known or proven to drive an immune response that would trigger GBS. 48

Bell’s palsy

Cases of Bell’s palsy were reported in participants in the mRNA COVID-19 vaccine clinical trials. However, there was not an excess of Bell’s palsy in the COVID-19 vaccine arm and the FDA does not consider these to be above the rate expected in the general population. They have not concluded these cases were caused by immunization. Therefore, the U.S. CDC recommends that individuals who have previously had Bell’s Palsy may receive an mRNA COVID-19 vaccine. 49

Multiple Sclerosis

Systematic reviews have not shown that vaccines cause or worsen multiple sclerosis. 50

Other vaccinations

COVID-19 vaccines can be given concomitantly with, or any time before or after any other live or inactivated vaccine.51-54

Are there specific recommendations or considerations for safe and/or most effective vaccine administration?

Aligned with the Canadian Rheumatology Association’s guidelines, 55 our recommendations are:

1) For patients on the following medications, there is no need to adjust or delay the medication:
   - Hydroxychloroquine,
   - Prednisone less than 20mg/day,
   - IVIg 34
   - Sulfasalazine,
   - Teriflunamide leflunomide,
   - Azathioprine,
   - Oral cyclophosphamide,
   - Tacrolimus tocilizumab,
   - Cyclosporin, interferons,
   - Glatiramer acetate,
   - Dimethyl fumerate,
   - Natalizumab.

2) For patients on the following medications, there are two options:
   a) Do not change medication dosing or
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

b) Adjust medication dosing to optimize the immune response to the vaccine:

   i. For patients on weekly methotrexate, an option is to skip the methotrexate dose the following week after each vaccine dose.

   ii. For patients on intravenous cyclophosphamide, an option is to take each vaccine dose at least one week prior to the next cyclophosphamide infusion.

   iii. For patients on rituximab or ocrelizumab, the COVID-19 vaccination should ideally be timed four to five months after their last infusion and two to four weeks prior to their next infusion, when possible, in order to optimize vaccine response. However, in patients who require immediate infusion or who are unable to optimize timing of infusion product and vaccine, it is likely more important to have the COVID-19 vaccine earlier than to delay based on timing of B-cell therapy.

   iv. For MS patients who are requiring first or repeat dosing of cladribine or alemtuzumab a delay could be considered until after full vaccine course plus four weeks. If treatment with alemtuzumab is required because of active disease, then vaccination will need to be delayed for 12 weeks after treatment dose. Bridging with natalizumab can be considered in order to give full vaccination before initiating alemtuzumab. Vaccination after cladribine can occur 4 weeks after treatment dose.

   v. For patients on mycophenolate mofetil, if the disease is stable, the medication may be held for one week following each COVID-19 dose.

   vi. For patients on prednisone 20mg/d or higher, consider waiting until the prednisone dose is tapered to below 20mg/d to receive both vaccine doses. (Note: for individuals with Duchenne’s Muscular Dystrophy on deflazacort, Parent Project Muscular Dystrophy and Muscular Dystrophy Canada recommend vaccination on current prednisone dose) Pediatric patients on high-dose steroids should consult with their pediatric rheumatologist to decide on the best time to receive the vaccine.

References


COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022


COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy
Updated: November 8, 2022


COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022


Authors

Dr. Kristine Chapman, Division of Neurology, Department of Medicine, University of British Columbia
COVID-19 Vaccines for People with Autoimmune Neuromuscular Disorders Receiving Immunosuppressive/Immunomodulating Therapy

Updated: November 8, 2022

Mary Nieforth, Operations Director, Vancouver Acute, Vancouver Coastal Health

Dr. Hannah Briemberg, Division of Neurology, Department of Medicine, University of British Columbia

Dr. Virginia Devonshire, Division of Neurology, Department of Medicine, University of British Columbia

Dr. Yahya Agha-Khani, Division of Neurology, Department of Medicine, University of British Columbia

Dr. Andrea Townson, Division of Physical Medicine and Rehabilitation, Department of Medicine, University of British Columbia

Dr. Jennifer Yao, Division of Physical Medicine and Rehabilitation, Department of Medicine, University of British Columbia

Dr. Kathryn Selby, Division of Neurology, Department of Pediatrics, University of British Columbia

Dr. Jeremy Road, Division of Respiratory Medicine, Department of Medicine, University of British Columbia

Dr. Marie Wright, Division of Respiratory Medicine, Department of Pediatrics, University of British Columbia